Skip to main content

Table 2 Distribution of failure, suboptimal and optimal collections in the whole population

From: Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell’Adulto Multiple Myeloma Working Party study

Parameters

Failure

Sub-Optimal

Optimal

Number (%)

Number (%)

Number (%)

Whole population

   

Outcome

167 (12.39)

113 (8.38)

1068 (79.23)

Age

   

 <60 years

80 (10.15)

57 (7.23)

651 (82.61)

 ≥60 years

87 (15.54)

56 (10.00)

417 (74.46)

Lenalidomide use

   

 No

113 (11.39)

78 (7.86)

801 (80.75)

 Yes

54 (15.17)

35 (9.83)

267 (75.00)

Hematological toxicity

   

 No

132 (10.48)

106 (8.41)

1022 (81.11)

 Yes

35 (39.77)

7 (7.95)

46 (52.27)

Baseline cytopenia

   

 No

117 (11.52)

80 (7.87)

819 (80.61)

 Yes

50 (15.06)

33 (9.94)

249 (75.00)

  1. Absolute numbers and percentages of failures, suboptimal and optimal collections, according to the presence of different risk factors in 1,348 newly diagnosed myeloma patients. Failure: CD34+ PBSC <2 × 106/kg; Suboptimal: CD34+ PBSC >2 and <5 × 106/kg; Optimal: CD34+ PBSC >5 × 106/kg. PBSC, peripheral blood stem cells.